An interventional study of Plasma osteoprotegerin level and Plasma fibroblast growth factor 23 level in Chronic Kidney Disease, sponsored by University Hospital, Montpellier. Recruiting at 7 sites in France. Open to participants aged 18 Years to 95 Years. Per ClinicalTrials.gov, last updated 2022-01-04.
Sponsored by University Hospital, Montpellier · Not applicable, Interventional, and Supportive care
To evaluate the relationships between bone mineral metabolism markers (osteoprotegerin, fibroblast growth factor 23) at inclusion and the occurence of cardiovascular events during a 7 year follow-up.
3,840 studies on the registry are indexed under Kidney Diseases; 500 are open to participants now.
This study's planned enrollment of 250 is above the median of 70 across 2,640 interventional studies indexed under Kidney Diseases.
Browse Kidney Diseases studies →University Hospital, Montpellier is the lead sponsor of 1,244 studies on the registry; 225 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Measurement at inclusion of plasma osteoprotegerin level, plasma fibroblast growth factor 23 level, vascular calcification score and record of cardiovascular events during the 3 year follow-up
Biological: Plasma osteoprotegerin level · Biological: Plasma fibroblast growth factor 23 level · Procedure: Vascular calcification score
dosage of plasma osteoprotegerin
dosage of plasma fibroblast growth factor 23
measurement of vascular calcification score by multidetection computerized tomography
Occurence of at least one cardiovascular event during the 7 year follow-up according to osteoprotegerin level at inclusion
osteoprotegerin will be measured in picomol/L
Time frame: 7 years after inclusion
Occurence of at least one cardiovascular event during the 7 year follow-up according to fibroblast growth factor 23 level at inclusion
fibroblast growth factor 23 will be measured in RU/milliliter
Time frame: 7 years after inclusion
Occurence of at least one cardiovascular event during the 7 year follow-up according to vascular calcification score at inclusion
Time frame: 7 years after inclusion
Mortality
Time frame: 7 years after inclusion
Kidney functions
values of creatinine
Time frame: during the 7 year follow-up
Plan to share: No
No publications or documents are linked to this record.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University Hospital, Montpellier